SCHEDULE: Scinai Immunotherapeutics Ltd. Ownership Filing Update

An amended Schedule 13G filing reveals updated beneficial ownership details for Scinai Immunotherapeutics Ltd. by Stone Daniel E. and RK Stone Miami, LLC.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership reporting for Scinai Immunotherapeutics Ltd.
• The filing details the ownership of American Depositary Shares (ADSs) by Daniel E. Stone and RK Stone Miami, LLC.
• As of June 3, 2026, the total outstanding ordinary shares were 20,053,835,584.
• Daniel E. Stone directly holds 496,332 ADSs.
• RK Stone Miami, LLC holds 357,006 ADSs and 32,326 ADSs issuable upon exercise of pre-funded warrants.
• On June 25, 2026, RK Stone Miami, LLC exercised 157,006 warrants.
• As of June 25, 2026, RK Stone Miami, LLC holds 357,006 ADSs and 692,505 ADS pre-funded warrants.
• The pre-funded warrants have an exercise limitation to prevent beneficial ownership exceeding 9.99% of ordinary shares.
• Future issuances by the company may allow more pre-funded warrants to become exercisable without increasing beneficial ownership percentage.
• The total beneficial ownership reported by both entities is 17.02% of the class of securities.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily a procedural update on ownership percentages and warrant exercises, without providing insights into the company's operational performance or future prospects.

Positives

• The filing clarifies beneficial ownership, providing transparency for investors.
• The exercise of warrants by RK Stone Miami, LLC on June 25, 2026, indicates continued investment or strategic interest.
• The structure of pre-funded warrants allows for potential future exercise while managing ownership thresholds.

Negatives

• The aggregate beneficial ownership is reported as 0 for both Daniel E. Stone and RK Stone Miami, LLC in specific categories (sole/shared dispositive power), which may require further clarification depending on the exact interpretation of 'beneficially owned' in this context.
• The limitation on exercising pre-funded warrants to maintain beneficial ownership below 9.99% could restrict immediate control or influence.

Risks

• The exercise limitation on pre-funded warrants could prevent the reporting persons from increasing their stake beyond 9.99%, potentially limiting their ability to influence company decisions if they desired to do so.
• Future issuances of shares by the company could dilute existing shareholders, including the reporting persons, if not managed strategically.
• The filing does not provide details on the underlying business performance or strategic direction of Scinai Immunotherapeutics Ltd., which are crucial for assessing investment risk.

Future Outlook

The filing mentions that future issuances of ordinary shares or ADSs by the issuer to third parties are expected to cause additional amounts of pre-funded warrants to become exercisable within the foregoing limitation, without increasing the reporting person's beneficial ownership percentage. This suggests a potential for increased share availability and exercise of warrants under specific conditions.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors and significant shareholders, indicating passive investment stakes. The details provided here are specific to ownership levels and do not reflect operational performance or strategic shifts within the biotechnology sector where Scinai Immunotherapeutics Ltd. operates.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership stakes.
• Management: Awareness of the beneficial ownership levels and potential influence thresholds.
• Potential Investors: Information on the holdings of Daniel E. Stone and RK Stone Miami, LLC can inform investment decisions.

Next Steps

• Monitor future filings for any changes in beneficial ownership.
• Observe the exercise of pre-funded warrants as conditions permit.
• Track company announcements for operational and strategic updates relevant to the biotechnology sector.

Key Dates

Keywords

Scinai Immunotherapeutics Ltd., Schedule 13G, Beneficial Ownership, American Depositary Shares, ADSs, Pre-funded Warrants, Daniel E. Stone, RK Stone Miami, LLC, SEC Filing, Ownership Threshold